Investor Presentation Report

I attended the Noxopharm presentation in Sydney on 2 June. It was brilliant.

It is now common knowledge that Graham Kelly is free of cancer, having failed all conventional therapy before being treated with the combination of NOX66 and low-dose radiation. GK explained that he was almost paralysed with pain at the time and that the best his specialist could offer was palliative radiation to two of the largest tumours as a form of pain relief. The response was extraordinary – those two tumours disappeared, as did all other pockets of cancer throughout his body, even though they had not been directly irradiated.

Co-presenter Ian Minns impressively demonstrated that Noxopharm is not a one-man band. Ian noted that radiation-combination trials should be easy to recruit as end-stage patients will simply be asked whether they wanted to add non-toxic NOX66 to their palliative radiation. Chemotherapy-combination patients, by contrast, will need to accept rechallenge with chemotherapy they may have previously failed. The difference here to a normal Phase Ia/1b trial is that all patients will receive NOX66 at a therapeutic level, plus chemo at non-toxic levels. Safety data will be available fairly quickly, but we may have to wait until the last quarter for efficacy data.

The most significant part of the presentation, in my view, related to Compassionate Treatment of rare cancers. This program started five or six months ago, with the Company supplying drug to treating oncologists, but Noxopharm has decided to launch a parallel study under its control so that the company owns the data. This is important on two fronts: it clearly implies that good responses have been seen with early Compassionate patients, otherwise the program would not have been expanded; and it provides an avenue of treatment for desperate people who have untreatable forms of cancer.

We should not forget that the control of cancer is our goal – the money will look after itself. NOX66 does not seek to kill cancer cells, merely to weaken them so that all existing drugs will be more effective. I can live with that.

We know that NOX66 worked for Graham Kelly and we can deduce that it is showing promise with early patients. If I or a loved one had cancer, the very first therapy I would want would include NOX66.